Abstract
We previously identified a Plasmodium falciparum (Pf) protein of unknown function encoded by a single-copy gene, PF3D7_1134300, as a target of antibodies in plasma of Tanzanian children in a whole-proteome differential screen. Here we characterize this protein as a blood-stage antigen that localizes to the surface membranes of both parasitized erythrocytes and merozoites, hence its designation as Pf erythrocyte membrane and merozoite antigen 1 (PfEMMA1). Mouse anti-PfEMMA1 antisera and affinity-purified human anti-PfEMMA1 antibodies inhibited growth of P. falciparum strains by up to 68% in growth inhibition assays. Following challenge with uniformly fatal Plasmodium berghei (Pb) ANKA, up to 40% of mice immunized with recombinant PbEMMA1 self-cured, and median survival of lethally infected mice was up to 2.6-fold longer than controls (21 vs. 8 d, P = 0.005). Furthermore, high levels of naturally acquired human anti-PfEMMA1 antibodies were associated with a 46% decrease in parasitemia over 2.5 yr of follow-up of Tanzanian children. Together, these findings suggest that antibodies to PfEMMA1 mediate protection against malaria.
Funding Information
  • National Institute of General Medical Sciences
  • National Institutes of Health (P20GM104317)
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health (R01AI142743-010, R01 AI136511)
  • Bill and Melinda Gates Foundation (OPP1158199)
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health (K08AI100997, R25AI140490)
  • Lifespan Inc.
  • Rhode Island Foundation
  • National Science Foundation
  • U.S. Department of Energy
  • Established Program to Stimulate Competitive Research (EPS-1004057)

This publication has 70 references indexed in Scilit: